Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology, urology areas are important to the firm because of huge unmet needs, Takeda tells “The Pink Sheet” DAILY.